<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carbohydrate and insulin metabolism in chronic kidney disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carbohydrate and insulin metabolism in chronic kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Carbohydrate and insulin metabolism in chronic kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Biff F Palmer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Advanced chronic kidney disease (CKD) is typically associated with impaired glucose metabolism. Some patients with CKD have hyperglycemia in response to oral and intravenous glucose loads, while others are able to maintain normoglycemia by raising plasma insulin levels. Studies utilizing the euglycemic and hyperglycemic clamp techniques suggest that several disturbances in carbohydrate handling may be present. Tissue insensitivity to insulin is of primary importance, but alterations in insulin degradation and insulin secretion also may contribute [<a href="#rid1">1-3</a>]. The variable severity of these changes in individual patients explains the variable plasma levels of insulin and glucose that may be seen both fasting and following a glucose load.</p><p>This topic will review the changes in carbohydrate and insulin metabolism that occur in CKD and the clinical implications of these abnormalities in patients without diabetes. The impact of these changes on the management of hyperglycemia in patients with diabetes and end-stage kidney disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1857.html" rel="external">"Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">NORMAL RENAL HANDLING OF INSULIN</span><span class="headingEndMark"> — </span>The kidney plays a central role in the metabolism of insulin in normal subjects [<a href="#rid1">1,2,4</a>]. Insulin has a molecular weight of 6000 and is therefore freely filtered. Of the total renal insulin clearance, approximately 60 percent occurs by glomerular filtration and 40 percent by extraction from the peritubular vessels. Insulin in the tubular lumen enters proximal tubular cells by carrier-mediated endocytosis and is then transported into lysosomes, where it is metabolized to amino acids [<a href="#rid5">5</a>]. The net effect is that &lt;1 percent of filtered insulin appears in the final urine.</p><p>The renal clearance of insulin is 200 mL/min, significantly exceeding the normal glomerular filtration rate (GFR) of 120 mL/min due to the contribution of tubular secretion. From this rate of renal clearance, it can be calculated that 6 to 8 units of insulin are degraded by the kidney each day, which accounts for approximately 25 percent of the daily production of insulin by the pancreas. The contribution of kidney metabolism is enhanced in diabetic subjects receiving exogenous insulin since injected insulin enters the systemic circulation directly, without first passing through the liver.</p><p class="headingAnchor" id="H3"><span class="h1">INSULIN RESISTANCE</span><span class="headingEndMark"> — </span>Impaired tissue sensitivity to insulin occurs in almost all patients with advanced CKD and is largely responsible for the abnormal glucose metabolism seen in this setting [<a href="#rid1">1-3</a>]. Possible mechanisms that could account for the reduction in insulin-mediated glucose handling include: (1) increased hepatic gluconeogenesis that does not suppress normally following insulin; (2) reduced hepatic and/or skeletal muscle glucose uptake; and (3) impaired intracellular glucose metabolism due either to decreased oxidation to carbon dioxide and water or to diminished synthesis of glycogen. Many of these effects have been linked to acquired abnormalities in intracellular signaling pathways, normally initiated by insulin binding to its receptor [<a href="#rid6">6</a>]. </p><p>Both experimental and clinical studies suggest that hepatic glucose production and uptake are normal in patients with CKD and that skeletal muscle is the primary site of insulin resistance [<a href="#rid1">1,2</a>]. How this occurs is not clear, but a postreceptor defect is of primary importance [<a href="#rid7">7,8</a>]. Furthermore, the abnormality appears to specifically involve glycogen synthesis as the rate of glucose oxidation is relatively normal [<a href="#rid8">8</a>]. It is of interest in this regard that other actions of insulin, such as promoting potassium uptake by the cells and inhibiting proteolysis, are also maintained in kidney failure [<a href="#rid8">8-10</a>]. (See  <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">"Treatment and prevention of hyperkalemia in adults"</a>.)</p><p>Accumulation of a uremic toxin or toxins and excess parathyroid hormone (PTH), resulting from abnormalities in phosphate and vitamin D metabolism (see  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>), are thought to be responsible for the insulin resistance [<a href="#rid11">11-13</a>]. As an example, the observation that tissue sensitivity to insulin can be substantially improved by dialysis is consistent with a role for uremic toxins [<a href="#rid2">2,11</a>].</p><p>There is also increasing evidence for an important role of PTH and <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> (1,25-dihydroxyvitamin D). In one study, for example, acute intravenous administration of calcitriol to hemodialysis patients enhanced insulin release and improved glucose tolerance [<a href="#rid12">12</a>]. This effect was independent of changes in the plasma concentrations of calcium or PTH. Two longer trials demonstrated that intravenous calcitriol essentially normalized insulin sensitivity [<a href="#rid13">13,14</a>]. Plasma PTH levels also fell so that it was not possible to determine whether the improvement was due to calcitriol per se and/or to reversal of hyperparathyroidism.</p><p>Impaired tissue sensitivity to insulin has also been demonstrated in patients with only mild to moderate reductions in kidney function [<a href="#rid15">15,16</a>]. Two observations suggest that decreased tissue oxygen delivery contributes to this abnormality:</p><p class="bulletIndent1"><span class="glyph">●</span>The degree of tissue insensitivity to insulin directly correlates with maximal aerobic work capacity, indicating that physical training may ameliorate insulin resistance in patients with kidney failure. Support for this hypothesis was provided by a study that noted that long-term exercise training in a group of patients on maintenance hemodialysis was associated with significantly reduced blood glucose levels, improved glucose disappearance rates, and reduced fasting serum insulin levels [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia also may be an important factor underlying insulin resistance in uremia as evidenced by an approximate 50 percent increase in insulin-induced glucose utilization following correction of anemia with erythropoietin [<a href="#rid18">18,19</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">INSULIN DEGRADATION</span><span class="headingEndMark"> — </span>There is little change in the metabolic clearance rate of insulin in kidney disease until there has been a substantial reduction in the glomerular filtration rate (GFR) [<a href="#rid1">1</a>]. Increased peritubular insulin uptake is able to compensate for reduced filtration until the GFR has fallen to less than 15 to 20 mL/min [<a href="#rid20">20</a>]. At this point, there is a dramatic reduction in insulin clearance that is also mediated by a concomitant decline in hepatic insulin metabolism [<a href="#rid1">1</a>]. The hepatic defect may be induced by a uremic toxin since it is largely reversed with adequate dialysis [<a href="#rid21">21</a>]. As will be discussed below, these findings may become important clinically in diabetic patients treated with insulin.</p><p class="headingAnchor" id="H5"><span class="h1">INSULIN SECRETION</span><span class="headingEndMark"> — </span>The expected response to impaired tissue sensitivity would be an augmentation in insulin secretion in an attempt to normalize glucose metabolism. In many cases, however, insulin secretion tends to be blunted; these patients tend to have the greatest impairment in glucose tolerance.</p><p>One factor that can suppress insulin release in chronic kidney disease (CKD) is the associated metabolic acidosis [<a href="#rid2">2</a>]. In addition, excess parathyroid hormone (PTH) may interfere with the ability of the beta cells to augment insulin secretion in response to hyperglycemia or amino acids [<a href="#rid22">22-24</a>]. A PTH-induced elevation in the intracellular calcium concentration may be responsible for the impairment in insulin release by decreasing both the cellular content of adenosine triphosphate (ATP) and Na-K-ATPase pump activity in the pancreatic beta cells [<a href="#rid25">25</a>]. In experimental animals, these changes can be prevented by prior parathyroidectomy or by the administration of the calcium channel blocker <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> [<a href="#rid23">23,24</a>].</p><p>The common deficiency of <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> (1,25-dihydroxyvitamin D) in CKD also may contribute to the impairment in insulin secretion. As an example, acute administration of calcitriol to hemodialysis patients has been shown to enhance insulin release and improve glucose tolerance [<a href="#rid12">12</a>]. This effect was independent of changes in the plasma concentrations of calcium or PTH. The importance of the inhibiting effect of PTH and the stimulating effect of calcitriol was also suggested in a case report of a patient who developed hypoglycemia with high insulin levels after the combination of parathyroidectomy and large doses of calcitriol [<a href="#rid26">26</a>].</p><p>As with the tissue sensitivity to insulin, hemodialysis has been shown to improve the insulin secretory response to glucose [<a href="#rid21">21</a>]. The mechanism by which this occurs has yet to be determined, but partial correction of the acidemia may contribute.</p><p>Studies evaluating the effect of erythropoietin on insulin and carbohydrate metabolism in CKD have produced conflicting results. In one report, for example, the administration of erythropoietin was associated with increased insulin secretion and decreased blood glucose levels following a test meal [<a href="#rid27">27</a>]. In another study, no change in these parameters was seen after an oral glucose load [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL IMPLICATIONS</span><span class="headingEndMark"> — </span>While sophisticated tests disclose resistance to the hypoglycemic activity of insulin in virtually all uremic subjects, most nondiabetic patients do not develop persistent hyperglycemia, unless they have a genetic predisposition to diabetes [<a href="#rid1">1,2</a>]. In this setting, inadequate insulin secretion may combine with uremic insulin resistance to produce overt diabetes.</p><p>The hyperinsulinemia normally induced by insulin resistance may also contribute to the common development of hypertriglyceridemia in chronic kidney disease (CKD) (see  <a class="medical medical_review" href="/z/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome"</a>). Insulin enhances hepatic very low density lipoprotein (VLDL) triglyceride synthesis and may indirectly (via decreased sensitivity of lipoprotein lipase to insulin) reduce the rate of metabolism of VLDL.</p><p>Hyperinsulinemia can also affect fibrinolysis by stimulating the production of plasminogen activator inhibitor-1. It may therefore play a role in the decreased systemic fibrinolytic activity characteristic of CKD [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Insulin requirements in diabetes mellitus</span><span class="headingEndMark"> — </span>Insulin requirements show a biphasic course in diabetic patients with kidney disease. It is not uncommon for glucose control to deteriorate as kidney function deteriorates, as increasing insulin resistance can affect patients with both type 1 and type 2 diabetes. Thus, insulin requirements may increase in the former, while the institution of insulin therapy may be necessary in the latter.</p><p>In comparison, the marked fall in insulin clearance in advanced kidney failure often leads to an improvement in glucose tolerance. This may allow a lower dose of insulin to be given or even the cessation of insulin therapy [<a href="#rid30">30,31</a>]. Decreased caloric intake due to uremia-induced anorexia also may contribute to the decrease in insulin requirements [<a href="#rid2">2</a>].</p><p>With the institution of hemodialysis, the insulin requirement in any given patient will depend upon the net balance between improving tissue sensitivity and restoring normal hepatic insulin metabolism. As a result, one cannot readily predict insulin requirements in this setting, and careful observation of the patient in essential. (See  <a class="medical medical_review" href="/z/d/html/1857.html" rel="external">"Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">HYPOGLYCEMIA</span><span class="headingEndMark"> — </span>An unusual manifestation of disturbed glucose metabolism in CKD is the development of spontaneous hypoglycemia [<a href="#rid2">2,32-34</a>]. This complication can be seen in patients with and without diabetes. As an example, in a retrospective analysis of 243,222 patients, the incidence of hypoglycemia was significantly higher among patients with CKD (defined as estimated glomerular filtration rate [eGFR] &lt;60 mL/min/1.73 m<sup>2</sup>) compared with patients without CKD both among those with diabetes (10.72 versus 5.33 per 100 patient-months, respectively) and without diabetes (3.46 versus 2.23 per 100 patient-months, respectively) [<a href="#rid35">35</a>].</p><p>Multiple factors may play a contributory role. These include decreased caloric intake, reduced renal gluconeogenesis due to the reduction in functioning kidney mass, impaired release of the counterregulatory hormone epinephrine due to the autonomic neuropathy of kidney failure, concurrent hepatic disease, and decreased metabolism of drugs that might promote a reduction in the plasma glucose concentration, such as alcohol, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and other nonselective blockers, and <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">disopyramide</a> [<a href="#rid2">2,33</a>].</p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired glucose metabolism</strong> – In patients with advanced chronic kidney disease (CKD), several disturbances in carbohydrate handling may be present. Tissue insensitivity to insulin is of primary importance, but alterations in insulin degradation and insulin secretion also may contribute. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal renal handling of insulin</strong> – The kidney plays a central role in the metabolism of insulin in normal individuals. Insulin is freely filtered in the kidney. Of the total renal insulin clearance, approximately 60 percent occurs by glomerular filtration and 40 percent by extraction from the peritubular vessels. (See <a class="local">'Normal renal handling of insulin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insulin resistance, clearance/degradation, and secretion</strong> – Impaired tissue sensitivity to insulin occurs in almost all subjects with advanced CKD and is largely responsible for the abnormal glucose metabolism seen in this setting. There is also a dramatic reduction in insulin clearance that is also mediated by a concomitant decline in hepatic insulin metabolism. Further, insulin secretion tends to be blunted. (See <a class="local">'Insulin resistance'</a> above and <a class="local">'Insulin degradation'</a> above and <a class="local">'insulin secretion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical implications</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without diabetes</strong> – Despite abnormalities in insulin metabolism, most patients without diabetes who have impaired kidney function do not develop persistent hyperglycemia unless they have a genetic predisposition to diabetes. (See <a class="local">'Clinical implications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with diabetes</strong> – Among patients with diabetes and kidney disease, insulin requirements show a biphasic course. Glucose control in patients with type 1 and type 2 diabetes commonly worsens as kidney function deteriorates, due to increasing insulin resistance. In comparison, the marked fall in insulin clearance in advanced CKD often leads to an improvement in glucose tolerance. This may allow a lower dose of insulin, conversion to oral therapy, or even the cessation of insulin therapy. (See <a class="local">'Insulin requirements in diabetes mellitus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spontaneous hypoglycemia</strong> – An unusual manifestation of disturbed glucose metabolism in CKD is the development of spontaneous hypoglycemia. Multiple factors may play a contributory role. (See <a class="local">'Hypoglycemia'</a> above.)</p><p></p><p class="headingAnchor" id="H820007707"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge William L Henrich, MD, MACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992; 61:377.</a></li><li><a class="nounderline abstract_t">Adrogué HJ. Glucose homeostasis and the kidney. Kidney Int 1992; 42:1266.</a></li><li><a class="nounderline abstract_t">Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int Suppl 1997; 62:S48.</a></li><li><a class="nounderline abstract_t">Rabkin R, Rubenstein AH, Colwell JA. Glomerular filtration and proximal tubular absorption of insulin 125 I. Am J Physiol 1972; 223:1093.</a></li><li><a class="nounderline abstract_t">Carone FA, Peterson DR. Hydrolysis and transport of small peptides by the proximal tubule. Am J Physiol 1980; 238:F151.</a></li><li><a class="nounderline abstract_t">Thomas SS, Zhang L, Mitch WE. Molecular mechanisms of insulin resistance in chronic kidney disease. Kidney Int 2015; 88:1233.</a></li><li><a class="nounderline abstract_t">Smith D, DeFronzo RA. Insulin resistance in uremia mediated by postbinding defects. Kidney Int 1982; 22:54.</a></li><li><a class="nounderline abstract_t">Castellino P, Solini A, Luzi L, et al. Glucose and amino acid metabolism in chronic renal failure: effect of insulin and amino acids. Am J Physiol 1992; 262:F168.</a></li><li><a class="nounderline abstract_t">Alvestrand A, Wahren J, Smith D, DeFronzo RA. Insulin-mediated potassium uptake is normal in uremic and healthy subjects. Am J Physiol 1984; 246:E174.</a></li><li><a class="nounderline abstract_t">Goecke IA, Bonilla S, Marusic ET, Alvo M. Enhanced insulin sensitivity in extrarenal potassium handling in uremic rats. Kidney Int 1991; 39:39.</a></li><li><a class="nounderline abstract_t">McCaleb ML, Izzo MS, Lockwood DH. Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest 1985; 75:391.</a></li><li><a class="nounderline abstract_t">Mak RH. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 1992; 41:1049.</a></li><li><a class="nounderline abstract_t">Kautzky-Willer A, Pacini G, Barnas U, et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995; 47:200.</a></li><li><a class="nounderline abstract_t">Lin SH, Lin YF, Lu KC, et al. Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin Sci (Lond) 1994; 87:533.</a></li><li><a class="nounderline abstract_t">Eidemak I, Feldt-Rasmussen B, Kanstrup IL, et al. Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia 1995; 38:565.</a></li><li><a class="nounderline abstract_t">Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53:1343.</a></li><li><a class="nounderline abstract_t">Goldberg AP, Geltman EM, Gavin JR 3rd, et al. Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients. Nephron 1986; 42:311.</a></li><li><a class="nounderline abstract_t">Borissova AM, Djambazova A, Todorov K, et al. Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on haemodialysis. Nephrol Dial Transplant 1993; 8:93.</a></li><li><a class="nounderline abstract_t">Mak RH. Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. J Pediatr 1996; 129:97.</a></li><li><a class="nounderline abstract_t">Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med 1970; 282:182.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 1978; 62:425.</a></li><li><a class="nounderline abstract_t">Fadda GZ, Hajjar SM, Perna AF, et al. On the mechanism of impaired insulin secretion in chronic renal failure. J Clin Invest 1991; 87:255.</a></li><li><a class="nounderline abstract_t">Perna AF, Fadda GZ, Zhou XJ, Massry SG. Mechanisms of impaired insulin secretion after chronic excess of parathyroid hormone. Am J Physiol 1990; 259:F210.</a></li><li><a class="nounderline abstract_t">Oh HY, Fadda GZ, Smogorzewski M, et al. Abnormal leucine-induced insulin secretion in chronic renal failure. Am J Physiol 1994; 267:F853.</a></li><li><a class="nounderline abstract_t">Hajjar SM, Fadda GZ, Thanakitcharu P, et al. Reduced activity of Na(+)-K+ ATPase of pancreatic islets in chronic renal failure: role of secondary hyperparathyroidism. J Am Soc Nephrol 1992; 2:1355.</a></li><li><a class="nounderline abstract_t">Nadkarni M, Berns JS, Rudnick MR, Cohen RM. Hypoglycemia with hyperinsulinemia in a chronic hemodialysis patient following parathyroidectomy. Nephron 1992; 60:100.</a></li><li><a class="nounderline abstract_t">Kokot F, Wiecek A, Grzeszczak W, et al. Influence of erythropoietin treatment on glucose tolerance, insulin, glucagon, gastrin and pancreatic polypeptide secretion in haemodialyzed patients with end-stage renal failure. Contrib Nephrol 1990; 87:42.</a></li><li><a class="nounderline abstract_t">Chagnac A, Weinstein T, Zevin D, et al. Effects of erythropoietin on glucose tolerance in hemodialysis patients. Clin Nephrol 1994; 42:398.</a></li><li><a class="nounderline abstract_t">Hong SY, Yang DH. Insulin levels and fibrinolytic activity in patients with end-stage renal disease. Nephron 1994; 68:329.</a></li><li><a class="nounderline abstract_t">RUNYAN JW Jr, HURWITZ D, ROBBINS SL. Effect of Kimmelstiel-Wilson syndrome on insulin requirements in diabetes. N Engl J Med 1955; 252:388.</a></li><li><a class="nounderline abstract_t">Weinrauch LA, Healy RW, Leland OS Jr, et al. Decreased insulin requirement in acute renal failure in diabetic nephropathy. Arch Intern Med 1978; 138:399.</a></li><li><a class="nounderline abstract_t">Peitzman SJ, Agarwal BN. Spontaneous hypoglycemia in end-stage renal failure. Nephron 1977; 19:131.</a></li><li><a class="nounderline abstract_t">Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 1989; 18:103.</a></li><li><a class="nounderline abstract_t">Ushiogi Y, Kanehara H, Kato T. Frequency of Hypoglycemia Assessed by Continuous Glucose Monitoring in Advanced CKD. Clin J Am Soc Nephrol 2023; 18:475.</a></li><li><a class="nounderline abstract_t">Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1121.</a></li></ol></div><div id="topicVersionRevision">Topic 1974 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1501732" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Glucose and insulin metabolism in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1453613" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Glucose homeostasis and the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9350680" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Carbohydrate and insulin metabolism in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4654343" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Glomerular filtration and proximal tubular absorption of insulin 125 I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6989268" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hydrolysis and transport of small peptides by the proximal tubule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26444029" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Molecular mechanisms of insulin resistance in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6750207" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Insulin resistance in uremia mediated by postbinding defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1539681" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Glucose and amino acid metabolism in chronic renal failure: effect of insulin and amino acids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6364842" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Insulin-mediated potassium uptake is normal in uremic and healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1672173" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Enhanced insulin sensitivity in extrarenal potassium handling in uremic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3882760" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Characterization and partial purification of a factor from uremic human serum that induces insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1513086" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7731147" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intravenous calcitriol normalizes insulin sensitivity in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7874841" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7489839" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9573550" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3960242" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8381946" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8757568" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5409813" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of renal disease on renal uptake and excretion of insulin in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/353075" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985099" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : On the mechanism of impaired insulin secretion in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2143630" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mechanisms of impaired insulin secretion after chronic excess of parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7977790" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Abnormal leucine-induced insulin secretion in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1320948" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Reduced activity of Na(+)-K+ ATPase of pancreatic islets in chronic renal failure: role of secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1738397" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hypoglycemia with hyperinsulinemia in a chronic hemodialysis patient following parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2093540" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Influence of erythropoietin treatment on glucose tolerance, insulin, glucagon, gastrin and pancreatic polypeptide secretion in haemodialyzed patients with end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7882604" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of erythropoietin on glucose tolerance in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7838255" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Insulin levels and fibrinolytic activity in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13236036" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of Kimmelstiel-Wilson syndrome on insulin requirements in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/629634" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Decreased insulin requirement in acute renal failure in diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19712" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Spontaneous hypoglycemia in end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2645122" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hypoglycemia associated with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36723294" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Frequency of Hypoglycemia Assessed by Continuous Glucose Monitoring in Advanced CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19423569" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Frequency of hypoglycemia and its significance in chronic kidney disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
